[A25-17] Marstacimab (haemophilia B) – Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2025
Project no.:
A25-17
Commission:
Commission awarded on 03.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-17
| Project no. | Title | Status |
|---|---|---|
| A25-16 | Marstacimab (haemophilia A) – Benefit assessment according to §35a Social Code Book V | Commission completed |